GLP-1 Medications in Japan: Complete Guide (2026)
Japan has taken a measured but increasingly progressive approach to GLP-1 medications. Wegovy (semaglutide) was approved for weight management and added to the national health insurance formulary in February 2024, making Japan one of the first Asian countries to cover an anti-obesity GLP-1. However, eligibility is strict: BMI 35+ or BMI 27+ with at least one obesity-related comorbidity. Zepbound (tirzepatide) was approved for obesity in January 2025. For diabetes, GLP-1 medications including Ozempic and RevoNate (tirzepatide, branded differently for diabetes in Japan) are covered under universal insurance.
Enzo's Tip
Japan's coverage of Wegovy is a big step forward, but the BMI criteria are strict. If you meet the thresholds, your national insurance will cover a significant portion of the cost. Enzo helps you track the health metrics your doctor needs to see!
Quick Facts
| Country | Japan |
| Health System | Universal health insurance |
| Currency | JPY |
| GLP-1 Medications Available | 9+ |
Meet Enzo — your GLP-1 companion
Dose tracking, side effect logging, and a cute cat cheering you on. Free to download.
Available Medications in Japan
Local & Generic Brands
Join thousands tracking their GLP-1 journey with Enzo
Dose tracking, side effect logging, and a cute cat cheering you on. Free to download.
Frequently Asked Questions
Medical Disclaimer: Enzo is a tracking companion, not a doctor. Always consult your healthcare provider before starting, stopping, or changing any medication. The information on this page is for educational purposes only and should not be considered medical advice. Individual results may vary.